# Sun Pharma

> Sun Pharmaceutical Industries is an India-headquartered global drugmaker whose unusually broad machine spans inexpensive generics, branded generics, consumer health products, active pharmaceutical ingredients and a growing portfolio of innovative medicines. Founded by Dilip Shanghvi in 1983, it operates more than 40 manufacturing facilities, reaches over 100 countries and uses its vertically integrated scale to serve patients, clinicians, pharmacies, hospitals, distributors and health systems while concentrating specialty investment in dermatology, ophthalmology and oncology.

- **Founded:** 1983
- **Headquarters:** Mumbai, India
- **Founders:** Dilip Shanghvi (Founder and Executive Chairman)
- **Team size:** 43,000+ employees on the corporate profile; the FY2024-25 sustainability presentation reports 51,000+ worldwide when executives on contract are included.
- **Products:** Generic and branded generic medicines, Innovative medicines, Complex formulations, Active pharmaceutical ingredients, Consumer healthcare
- **Notable:** India’s No. 1 pharmaceutical company, with an 8.5% domestic market share reported for June 2026., Medicines sold in more than 100 countries through over 40 manufacturing facilities., Global innovative medicines reached US$1.42 billion in FY2025-26 and 20.7% of sales excluding milestone effects.

## Products & services

- **Generic and branded generic medicines** — A large global portfolio across chronic and acute therapies, including neuropsychiatry, cardiology, gastroenterology, anti-infectives and diabetes.
- **Innovative medicines** — Patent-protected products and pipeline assets focused on dermatology, ophthalmology and oncology, including ILUMYA, LEQSELVI, WINLEVI, CEQUA and UNLOXCYT.
- **Complex formulations** — Technology-intensive dosage forms such as liposomal drugs, inhalers, lyophilized injections, nasal sprays and controlled-release products.
- **Active pharmaceutical ingredients** — API and intermediate development and manufacturing for Sun Pharma’s own formulations and external customers.
- **Consumer healthcare** — Over-the-counter and consumer brands, including Revital and other market-specific wellness and treatment products.

## Achievements

- India’s No. 1 pharmaceutical company, with an 8.5% domestic market share reported for June 2026.
- Medicines sold in more than 100 countries through over 40 manufacturing facilities.
- Global innovative medicines reached US$1.42 billion in FY2025-26 and 20.7% of sales excluding milestone effects.
- More than 550 approved ANDAs and 57 approved NDAs in the U.S. portfolio as of mid-2026.
- Founder Dilip Shanghvi received India’s Padma Shri in 2016.
- Recognized among the top 5% of pharmaceutical companies in the S&P Global Sustainability Yearbook 2025.
- Great Place to Work certification across 25 countries based on a survey involving more than 38,000 employees.

## Latest updates

- **2026-07** — Reported Q1FY27 sales of INR 151.8 billion, up 10.1% year over year; innovative medicines represented 21.9% of sales.
- **2026-07** — Received or announced approvals and launches for generic semaglutide in Brazil and South Africa; the company also reported Organon shareholder approval for the proposed acquisition.
- **2026-05** — Reported FY26 sales of INR 582.2 billion and innovative-medicines sales of US$1.42 billion.
- **2026-04** — Signed a definitive agreement to acquire Organon for US$14 per share in cash, implying an enterprise value of US$11.75 billion; closing was targeted for early 2027 subject to conditions.
- **2026-03** — Launched semaglutide injection in India under the Noveltreat and Sematrinity brands.
- **2026-01** — Made UNLOXCYT available in the United States for advanced cutaneous squamous cell carcinoma.

## Links

- Website: https://sunpharma.com
- LinkedIn: https://www.linkedin.com/company/sun-pharma
- Twitter/X: https://twitter.com/SunPharma_Live
- YouTube: https://www.youtube.com/channel/UCdkyfWmDFAaUA5P8GD_LVdQ
- Facebook: https://www.facebook.com/SunPharmaLive/

---

Profile page: https://yespress.io/sun-pharma
Published by YesPress — https://yespress.io
Last updated: 2026-08-11